ArticleDigestive diseases and sciences2025
Use of Angiotensin Receptor Blockers in Celiac Disease Associated with Worse Outcomes.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Treatment Hinders Healing-Angiotensin Receptor Blockers and Malabsorptive Risk in Patients with Celiac Disease.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAngiotensin receptor blocker-associated enteropathy and celiac disease share similarities, including pathophysiology. Only one single-center study has examined the safety of these medications in celiac disease, and found that they may lead to worse outcomes.
aimsWe aimed to address this question using a larger cohort from a national database.
methodsWe analyzed the All of Us Research Program database and identified celiac disease using SNOMED terms. Prescription data identified angiotensin receptor blocker prescriptions. Outcomes of interest included symptoms (abdominal pain, diarrhea, weight loss) and surrogate markers of malabsorption (iron deficiency, vitamin deficiency, low hemoglobin). Survival analysis was performed to determine the association between angiotensin receptor blocker prescription and outcomes of interest in those with celiac disease.
results1849 individuals with celiac disease (1460 females, 389 males) were identified. Of those with celiac disease, 262 were prescribed an angiotensin receptor blocker. Those with celiac disease had significantly greater hazard for low hemoglobin (p = 5.9 × 10
conclusionsPrescription of angiotensin receptor blockers in celiac disease is associated with persistent symptoms and surrogate markers of malabsorption. Further research is needed to determine if this reflects an underlying interaction between the indication for these medications and celiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.